Cryoport (NASDAQ:CYRX) Given New $11.00 Price Target at UBS Group

Cryoport (NASDAQ:CYRX) had its target price lifted by UBS Group from $10.00 to $11.00 in a report released on Tuesday morning,Benzinga reports. UBS Group currently has a buy rating on the stock.

A number of other analysts also recently issued reports on CYRX. Guggenheim began coverage on shares of Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of Cryoport in a research report on Monday. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $11.83.

Cryoport Trading Up 0.2 %

Shares of CYRX stock opened at $6.09 on Tuesday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 5.32 and a current ratio of 5.70. The stock has a fifty day simple moving average of $6.61 and a two-hundred day simple moving average of $7.28. The firm has a market capitalization of $303.95 million, a PE ratio of -1.80 and a beta of 1.67. Cryoport has a 52-week low of $4.58 and a 52-week high of $20.11.

Cryoport (NASDAQ:CYRX) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.09). The business had revenue of $59.53 million during the quarter, compared to the consensus estimate of $58.71 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. During the same period last year, the company earned ($0.29) EPS. On average, analysts predict that Cryoport will post -0.99 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Jerrell Shelton sold 4,620 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $6.29, for a total value of $29,059.80. Following the sale, the chief executive officer now owns 765,399 shares of the company’s stock, valued at approximately $4,814,359.71. This represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold 19,830 shares of company stock valued at $118,353 over the last ninety days. 10.10% of the stock is owned by insiders.

Institutional Trading of Cryoport

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CYRX. Point72 Asia Singapore Pte. Ltd. boosted its position in shares of Cryoport by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock valued at $28,000 after buying an additional 2,120 shares during the period. Lazard Asset Management LLC bought a new position in Cryoport in the 4th quarter valued at $51,000. Avanza Fonder AB bought a new position in Cryoport in the 4th quarter valued at $64,000. Quarry LP bought a new position in shares of Cryoport in the fourth quarter worth about $69,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in Cryoport in the 3rd quarter worth about $82,000. 92.90% of the stock is owned by hedge funds and other institutional investors.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.